Van Tuyl Christopher 4

What Happened Christopher Van Tuyl, Chief Legal Officer of Immunovant (IMVT), sold 2,877 shares on March 18, 2026 at $24.97 per share, generating proceeds of $71,839. The sale is reported as a Section 16 sale (code S) and was executed to cover tax withholding associated with vested restricted stock units (RSUs), not as a discretionary sale.

Key Details

• Transaction date: 2026-03-18; sale price: $24.97; shares sold: 2,877; proceeds: $71,839.
• Form 4 filed: 2026-03-20 (timely filing).
• Footnote: On Dec 16, 2024 the Reporting Person was granted 109,956 RSUs; 6,872 RSUs vested on Mar 16, 2026. The 2,877 shares sold were to satisfy tax withholding tied to that vesting (sell-to-cover).
• The filing states the sale was mandated by the issuer’s sell-to-cover election and was not a discretionary transaction by the reporting person.
• Remaining shares from the vested tranche: 6,872 vested − 2,877 sold = 3,995 shares retained from that vesting event (this does not include any other holdings the insider may have).

Context Sell-to-cover transactions are common when RSUs vest and generally reflect tax-withholding mechanics rather than a signal about the insider’s view of the company. This was not a purchase or an exercise-and-sell; it was a tax-withholding sale tied to RSU settlement.